Journal
JAMA CARDIOLOGY
Volume 3, Issue 6, Pages 489-497Publisher
AMER MEDICAL ASSOC
DOI: 10.1001/jamacardio.2018.0579
Keywords
-
Categories
Funding
- American Heart Association
- Medtronic
- GlaxoSmithKline
- Ortho-McNeil Pharmaceutical
- American Heart Association Pharmaceutical Roundtable
Ask authors/readers for more resources
IMPORTANCE Among patients hospitalized with heart failure (HF), the long-term clinical implications of hospitalization at hospitals based on 30-day risk-standardized mortality rates (RSMRs) is not known. OBJECTIVE To evaluate the association of hospital-specific 30-day RSMR with long-term survival among patients hospitalized with HF in the American Heart Association Get With The Guidelines-HF registry. DESIGN, SETTING, AND PARTICIPANTS The longitudinal observational study included 106 304 patients with HF who were admitted to 317 centers participating in the Get With The Guidelines-HF registry from January 1, 2005, to December 31, 2013, and had Medicare-linked follow-up data. Hospital-specific 30-day RSMR was calculated using a hierarchical logistic regression model. In the model, 30-day mortality rate was a binary outcome, patient baseline characteristics were included as covariates, and the hospitals were treated as random effects. The association of 30-day RSMR-based hospital groups (low to high 30-day RSMR: quartile 1 [Q1) to Q4) with long-term (1-year, 3-year, and 5-year) mortality was assessed using adjusted Cox models. Data analysis took place from June 29, 2017, to February 19, 2018. EXPOSURES Thirty-day RSMR for participating hospitals. MAIN OUTCOMES AND MEASURES One-year, 3-year, and 5-year mortality rates. RESULTS Of the 106 304 patients included in the analysis. 57 552 (54.1%) were women and 84 595 (79.6%) were white, and the median (interquartile range) age was 81(74-87) years. The 30-day RSMR ranged from 8.6% (01) to 10.7% (Q4). Hospitals in the low 30-day RSMR group had greater availability of advanced HF therapies, cardiac surgery, and percutaneous coronary interventions. In the primary landmarked analyses among 30-day survivors, there was a graded inverse association between 30-day RSMR and long-term mortality (Q1 vs Q4: 5-year mortality, 733% vs 76.8%). In adjusted analysis, patients admitted to hospitals in the high 30-day RSMR group had 14% (95% CI, 10-18) higher relative hazards of 5-year mortality compared with those admitted to hospitals in the low 30-day RSMR group. Similar findings were observed in analyses of survival from admission, with 22% (95% CI, 18-26) higher relative hazards of 5-year mortality for patients admitted to Q4 vs Q1 hospitals. CONCLUSIONS AND RELEVANCE Lower hospital-level 30-day RSMR is associated with greater 1-year, 3-year, and 5-year survival for patients with HF. These differences in 30-day survival continued to accrue beyond 30 days and persisted long term, suggesting that 30-day RSMR may be a useful HF performance metric to incentivize quality care and improve long-term outcomes.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available